Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remygen
- Development stage
- Phase 2
- Lead developer
- Diamyd Medical
- Modality
- Targeted Protein Degraders (TPDs) → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Remygen is a proprietary controlled-release oral formulation of gamma-aminobutyric acid (GABA) developed by Diamyd Medical. GABA is a key cell signaling molecule in the pancreatic islets of Langerhans and has been shown to influence both insulin and glucagon secretion. Remygen is being investigated primarily for its potential to regenerate endogenous insulin production and improve hormonal counter-regulatory responses in individuals with long-standing type 1 diabetes. Preclinical studies suggest that GABA can stimulate the growth and function of pancreatic beta cells (insulin-producing) and alpha cells (glucagon-producing), while clinical trials have demonstrated improved protective hormonal responses against hypoglycemia during treatment. The drug may also be evaluated in combination with alprazolam, a GABA receptor modulator, to enhance its effects on beta cell function[1][3][5][6].
- Brand names
- Remygen
- Other names
- GABA - DiamydGamma-amino-butyric-acid-DiamydOral GABA Therapy - Diamyd
02
Targets
GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on remygen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remygen.